Limited expression of cancer-testis antigens in renal cell carcinoma patients

Soga, Norihito; Hori, Yasuhide; Yamakado, Koichiro; Ikeda, Hiroaki; Imai, Naoko; Kageyama, Shinichi; Nakase, Kazunori; Abe, Yuta; Hayashi, Norio; Shiku, Hiroshi; Sugimura, Yoshiki

doi:10.3892/mco.2012.40

Cited by 9 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shared tumor antigens, such as cancer-testis antigens, are also expressed in a limited manner (48,49). In a recent report (41), the expression of several endogenous retrovirus (ERV) genes was positively correlated with immune cytolytic activity in ccRCC patients, suggesting that ERV is likely to be involved in antitumor immunity in these patients.…”

Section: Discussionmentioning

confidence: 99%

Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma

Matsushita

Sato

Karasaki

et al. 2016

Cancer Immunology Research

View full text Add to dashboard Cite

Tumors commonly harbor multiple genetic alterations, some of which initiate tumorigenesis. Among these, some tumorspecific somatic mutations resulting in mutated protein have the potential to induce antitumor immune responses. To examine the relevance of the latter to immune responses in the tumor and to patient outcomes, we used datasets of wholeexome and RNA sequencing from 97 clear cell renal cell carcinoma (ccRCC) patients to identify neoepitopes predicted to be presented by each patient's autologous HLA molecules. We found that the number of nonsilent or missense mutations did not correlate with patient prognosis. However, combining the number of HLA-restricted neoepitopes with the cell surface expression of HLA or b 2 -microglobulin (b 2 M) revealed that an A-neo hi /HLA-A hi or ABC-neo hi /b 2 M hi phenotype correlated with better clinical outcomes. Higher expression of immune-

show abstract

Section: Discussionmentioning

confidence: 99%

Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma

Matsushita

Sato

Karasaki

et al. 2016

Cancer Immunology Research

View full text Add to dashboard Cite

show abstract

“…MAGE-A4 expression was assessed by immunohistochemistry (IHC) using the monoclonal antibodies 57B, MCV-1, and MCV-4, as previously described [ 17 ], or by quantitative real-time PCR (qRT-PCR) using specific primers [ 18 ]. NY-ESO-1 expression was assessed by immunohistochemistry with the monoclonal antibody E978 (Sigma-Aldrich, Saint Louis, MO) [ 19 ], or quantitative qRT-PCR using specific primers [ 18 ]. Tissue samples with a 5% or higher positively stained area were judged as antigen positive.…”

Section: Methodsmentioning

confidence: 99%

NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma

et al. 2018

Self Cite

View full text Add to dashboard Cite

MAGE-A4 antigen is a cancer-testis antigen that is frequently expressed in tumor tissues. Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received a CHP-MAGE-A4 vaccine. Twenty-two patients with advanced or metastatic cancer were enrolled, and were subcutaneously vaccinated with either 100 μg or 300 μg of CHP-MAGE-A4. Seven and 15 patients, respectively, were repeatedly vaccinated with 100 μg or 300 μg of CHP-MAGE-A4; patients in both groups received a median of 7 doses. No serious adverse events related to the vaccine were observed. Of 7 patients receiving the 100 μg dose, 2 (29%) showed immune responses, compared with 3 of the 14 (21%) patients who received the 300 μg dose. In total, MAGE-A4-specific antibody responses were induced in 5 of 21 (24%) patients. No differences in survival were seen between patients receiving the 100 μg and 300 μg doses, or between immune responders and non-responders. Eleven (50%) patients had pre-existing antibodies to NY-ESO-1. In 16 patients with esophageal or head/neck squamous cell carcinoma, the survival time was significantly shorter in those who had NY-ESO-1-co-expressing tumors. Patients with high pre-existing antibody responses to NY-ESO-1 displayed worse prognosis than those with no pre-existing response. Therefore, in planning clinical trials of MAGE-A4 vaccine, enrolling NY-ESO-1-expressing tumor or not would be a critical issue to be discussed. Combination vaccines of MAGE-A4 and NY-ESO-1 antigens would be one of the strategies to overcome the poor prognosis.

show abstract

“…RNA extraction was performed as described previously [20]. In brief, total RNA was extracted from frozen tissue samples, and complementary DNA (cDNA) was then prepared using a QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany).…”

Section: Mage-a4 Ny-eso-1 and Sage Expressionmentioning

confidence: 99%

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Cancer testis (CT) antigens are promising targets for cancer immunotherapies such as cancer vaccines and genetically modified adoptive T cell therapy. In this study, we evaluated the expression of three CT antigens, melanoma-associated antigen A4 (MAGE-A4), New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) and sarcoma antigen gene (SAGE). Methods: MAGE-A4, NY-ESO-1 and/or SAGE antigen expression in tumour samples was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Informed consent was obtained from individuals prior to study enrolment. Results: In total, 585 samples in 21 tumour types were evaluated between June 2009 and March 2018. The positive expression rates of these CT antigens were as follows: MAGE-A4, 34.6% (range, 30.7-38.7); NY-ESO-1, 21.0% (range, 17.2-25.1); and SAGE, 21.8% (range, 18.5-25.4). The MAGE-A4 antigen was expressed in 54.9% of oesophageal cancers, 37.5% of head and neck cancers, 35.0% of gastric cancers and 34.2% of ovarian cancers; the NY-ESO-1 antigen was expressed in 28.6% of lung cancers, 25.3% of oesophageal cancers and 22.6% of ovarian cancers; and the SAGE antigen was expressed in 35.3% of prostate cancers, 32.9% of oesophageal cancers and 26.3% of ovarian cancers. The most common tumour type in this study was oesophageal cancer. MAGE-A4, NY-ESO-1 and SAGE antigen expression were assessed in 214 oesophageal cancer samples, among which 24 (11.2%) were triple-positive, 58 (27.1%) were positive for any two, 59 (27.6%) were positive for any one, and 73 (34.1%) were triple negative. Conclusions: Oesophageal cancer exhibited a relatively high rate of CT antigen mRNA expression positivity.

show abstract

Limited expression of cancer-testis antigens in renal cell carcinoma patients

Cited by 9 publications

References 28 publications

Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma

Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma

NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

Contact Info

Product

Resources

About